Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15282
Abstract: AIM Clopidogrel is used as secondary prevention after cerebral ischemia. Previous - mainly Asian - studies have shown that genetic variations in CYP2C19 are associated with an increased risk of recurrent stroke in clopidogrel-treated patients.… read more here.
Keywords: cyp2c19; cerebral ischemia; treated patients; recurrent cerebral ... See more keywords